UPDATE: President & CEO Nikolaos Tezapsidis, Ph.D., Of Neurotez, Inc. To Be Interviewed Live On Clear Channel’s “The Trader’s Network Show”

(Click here for details)
UPDATE: President & CEO Nikolaos Tezapsidis, Ph.D., of Neurotez, Inc. to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”

(Click here for details)
Public Relations and Marketing by 1-800-PublicRelations, Inc.

BRIDGEWATER, NJ--(Marketwired - March 20, 2015) - Neurotez, Inc., a private corporation whose primary goal is to develop a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD), announced today that its President and Chief Executive Officer (CEO), Nikolaos Tezapsidis, will be interviewed live on Saturday, March 21, 2015 at 2:30pm ET by host Michael Yorba on Clear Channel -- iHeart Business Talk Radio’s “The Trader’s Network Show.” In this exclusive interview, Dr. Tezapsidis will discuss how a wide spectrum of preclinical findings, in addition to observational human studies and anecdotal interventional clinical studies strongly support the likelihood that Leptin augmentation will effectively slow or stop the progression of AD and may even preclude or delay the onset of cognitive decline in pre-impairment individuals, particularly for a well-defined subset.

We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide stream are below.

Date: March 21, 2015
Start Time: 2:30pm ET | 11:30am PT | 1:30pm CT
Network: Clear Channel/ iHeart Radio
Station: DFW 1190AM KFXR
KFXR Show: The Traders Network Show
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit its website at www.clearchannel.com.

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am - 8am, Monday-Friday and Saturdays from 1pm - 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more... shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.

About President and CEO Nikolaos Tezapsidis, Ph.D.
Dr. Tezapsidis founded Neurotez in 2004. He is President and Chief Executive Officer and Chairman of the Board of Directors and has held these positions since the company was incorporated in 2005. Nikolaos has successfully raised funds primarily through non-dilutive grant sources, but also through equity-based deals. While building the company, he recruited top talent, maintaining top notch research and development programs and establishing a strong patent portfolio (more than 20 patents globally are either pending or issued). Having held several positions at a number of prominent academic institutions, Dr. Tezapsidis has more than 18 years of international biomedical research experience. Prior to forming Neurotez, Dr. Tezapsidis served as a scientific consultant to biotechnology investors, providing highly regarded expertise.

From 2001 to 2004 he led a research group at Columbia University. Before joining Columbia University, Dr. Tezapsidis held faculty positions at New York University Medical School (2000-2001) and at Mount Sinai School of Medicine (MSSM), New York (1997-1998) and was Laboratory Director at the Institute for Basic Research, New York (1998-2000). He also conducted mentored research at MSSM (1994-1997), the Uniformed Services University of the Health Sciences, Bethesda (1992-1994) and at the Imperial College of Science, Technology and Medicine, University of London, UK (1990-1992). He has more than 50 scientific publications.

Among his career honors he received two awards from the Alzheimer’s Association, USA and fellowships from the Wellcome Trust and the Science and Engineering Council, UK. Dr. Tezapsidis received a Bachelor of Science in Chemistry from the Aristotle University, Greece and completed his Master of Science and Doctor of Philosophy in Biochemistry at the University of Sussex, UK.

About Neurotez, Inc.
Neurotez, Inc. is a private corporation whose primary goal is to develop a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk. Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain. This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels. The administration of Leptin inhibits both the production of amyloid beta (Aβ) and also the phosphorylation of tau protein in a variety of in vitro and in vivo systems. Since Aβ and phospho-tau are widely viewed as two of the key factors in Alzheimer’s disease etiology, Leptin represents a highly attractive, multi-functional therapeutic approach. Perhaps most tellingly, Neurotez has demonstrated that the administration of Leptin significantly improves cognition across a variety of measures in transgenic mouse models of AD. Thus, a wide spectrum of preclinical findings along with the human studies strongly support the likelihood that Leptin augmentation will effectively slow or stop the progression of AD and may even preclude or delay the onset of cognitive decline in pre-impairment individuals.

A 1800PublicRelations.com PR Event.